Register for our free email digests:
European Performance Tracker
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
New EU Approvals
The Pink Sheet’s list of EU centralized approvals of new active substances now includes two new products, one of which is the injectable migraine prevention drug, Ajovy (fremanezumab). The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
EU Accelerated Assessment Tracker
European CHMP Opinions and MAA Updates
This is a monthly update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
EU Biosimilar Filings, Opinions And Approvals
EU Accelerated Assessment Tracker: Nine Definites So Far From 24 Requests In 2018
In 2018, the European Medicines Agency considered 24 requests from drug companies for fast-track review of their planned marketing authorization applications. The agency has granted at least nine requests, eleven have been rejected and the results of four have yet to be disclosed.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.